Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug


Alnylam Pharmaceuticals last week released preclinical data demonstrating proof of concept for its porphyria treatment ALN-AS1.

The drug is designed to silence ALAS-1, a liver-expressed rate-limiting enzyme upstream of porphobilinogen deaminase. Inhibition of ALAS-1 has been shown to reduce the accumulation of heme precursors that cause the clinical manifestations of acute intermittent porphyria — a form of porphyria Alnylam is focusing on.

The new data show that ALN-AS1 “completely protected mice from phenobarbital-induced up-regulation of hepatic ALAS-1 mRNA and the resulting accumulation of the neurotoxic ALA and PBG heme biosynthesis precursors,” Alnylam said.

This protective effect was dose responsive and durable, lasting for at least two weeks after a single administration.

“Further, in a treatment model, a single dose of ALAS-1 siRNA rapidly reduced the high levels of plasma ALA and PBG that were elevated during a phenobarbital-induced acute attack,” Alnylam said. Meanwhile, preliminary comparative studies show that the drug was more effective than heme administration in the treatment of an acute attack.

Alnylam said that efforts to develop its GalNAc conjugation technology for use with ALN-AS1 have been promising, and that it remains on track to file an investigational new drug application for the compound in 2014.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.